Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
128 hot topic(s) found with the query "Pancreatic cancer"

Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma
L Jiang et al, Nature Medicine, January 29, 2024 (Posted: Jan 29, 2024 8AM)

From the abstract: "Adjuvant chemotherapy benefits patients with resected pancreatic ductal adenocarcinoma (PDAC), but the compromised physical state of post-operative patients can hinder compliance. Biomarkers that identify candidates for prompt adjuvant therapy are needed. In this prospective observational study, 1,171 patients with PDAC who underwent pancreatectomy were enrolled and extensively followed-up. Proteomic profiling of 191 patient samples unveiled clinically relevant functional protein modules. A proteomics-level prognostic risk model was established for PDAC, with its utility further validated using a publicly available external cohort. "


Do polygenic risk scores add to clinical data in predicting pancreatic cancer? a scoping review.
Louise Wang et al. Cancer Epidemiol Biomarkers Prev 2023 8 (Posted: Sep 16, 2023 1PM)

From the abstract: "21 studies examined associations between a PC-specific PRS and PC. Seven studies evaluated risk factors beyond age and sex. Three studies evaluated the change in discrimination associated with the addition of PRS to routine risk factors and reported improvements [(AUCs: 0.715 to 0.745; AUC 0.791 to 0.830; AUC from 0.694 to 0.711]. Limitations to clinical applicability included using source populations younger/healthier than those at risk for PC (n=10), exclusively of European ancestry (n=13), or controls without relevant exposures (n=1). While most studies of PC-specific PRS did not evaluate the independent discrimination of PRS for PC beyond routine risk factors, three that did showed improvements in discrimination. "


Precision medicine meets cancer vaccines.
et al. Nat Med 2023 6 (Posted: Jun 22, 2023 7AM)

Vaccines for treating cancer have been in development for decades, but their clinical efficacy has been elusive. Thus far, only one therapeutic vaccine against cancer has been approved by the US Food and Drug Administration for the treatment of prostate cancer, extending patient survival by only 4 months. Now, two independent efforts using mRNA vaccines tailor-made to target each patient’s tumor have reported initial success in melanoma and pancreatic cancer and are energizing the field of anti-cancer vaccines.


A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories.
Davide Placido et al. Nat Med 2023 5 (Posted: May 09, 2023 5AM)

Pancreatic cancer is an aggressive disease that typically presents late with poor outcomes, indicating a pronounced need for early detection. In this study, we applied artificial intelligence methods to clinical data from 6 million patients (24,000 pancreatic cancer cases) in Denmark (Danish National Patient Registry (DNPR)) and from 3 million patients (3,900 cases) in the United States (US Veterans Affairs (US-VA)). We trained machine learning models on the sequence of disease codes in clinical histories and tested prediction of cancer occurrence within incremental time windows (CancerRiskNet).


A Double Whammy on Gastric Cancer Risk.
Anne Müller et al. The New England journal of medicine 2023 3 (13) 1225-1229 (Posted: Mar 30, 2023 4PM)

Germline mutations in genes encoding homologous-recombination proteins are associated with cancer predisposition, developmental disorders, and premature aging. Specifically, germline pathogenic variants in ATM, BRCA2, BRCA1, and PALB2 are known to cause a predisposition to breast, ovarian, prostate, and pancreatic cancer. Gastric cancer, at least in the context of H. pylori infection, has now been added to this list.


Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
JH Stickler et al, NEJM, December 21, 2022 (Posted: Dec 22, 2022 8AM)

We conducted a single-group, phase 1–2 trial to assess the safety and efficacy of sotorasib treatment in patients with KRAS p.G12C–mutated pancreatic cancer who had received at least one previous systemic therapy. The primary objective of phase 1 was to assess safety and to identify the recommended dose for phase 2. Sotorasib showed anticancer activity and had an acceptable safety profile in patients with KRAS p.G12C–mutated advanced pancreatic cancer who had received previous treatment.


Pancreatic Cancer: Beyond Brca Mutations
V Ricci et al, J Per Med, December 16, 2022 (Posted: Dec 17, 2022 9AM)

Pancreatic cancer is the fourth-leading cause of cancer-related deaths worldwide. The outcomes in patients with pancreatic cancer remain unsatisfactory. In the current review, we summarize the genetic and epigenetic architecture of metastatic pancreatic cancer beyond the BRCA mutations, focusing on the genetic alterations and the molecular pathology in pancreatic cancer. This review focuses on the molecular targets for the treatment of pancreatic cancer, with a correlation to future treatments. The potential approach addressed in this review may lead to the identification of a subset of patients with specific biological behaviors and treatment responses.


Targeting KRAS in Pancreatic Cancer
D Cowser et al, J Per Med, November 8, 2022 (Posted: Nov 09, 2022 8AM)

Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.


Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction
NA Fraunhoffer et al, NPJ Precision Oncology, August 17, 2022 (Posted: Aug 18, 2022 1PM)

Pancreatic ductal adenocarcinoma (PDAC), has recently been found to be a heterogeneous disease, although the extension of its diversity remains to be fully understood. Here, we harmonize transcriptomic profiles derived from both PDAC epithelial and microenvironment cells to develop a Master Regulators (MR)-Gradient model that allows important inferences on transcriptional networks, epigenomic states, and metabolomics pathways that underlies this disease heterogeneity.


Translational advances in pancreatic ductal adenocarcinoma therapy.
Hosein Abdel Nasser et al. Nature cancer 2022 3 (3) 272-286 (Posted: Mar 31, 2022 8AM)

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently detected at advanced stages, limiting treatment options to systemic chemotherapy with modest clinical responses. Here, we review recent advances in targeted therapy and immunotherapy for treating subtypes of PDAC with diverse molecular alterations. We focus on the current preclinical and clinical evidence supporting the potential of these approaches and the promise of combinatorial regimens to improve the lives of patients with PDAC


Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
AA Connor et al, Nat Rev Cancer, November 17, 2021 (Posted: Nov 17, 2021 10AM)

Decades of research have improved our understanding of pancreatic cancer, including characterizing germline predisposition, the cell of origin, precursor lesions, the sequence of genetic alterations, including simple and structural alterations, transcriptional changes and subtypes, tumor heterogeneity, metastatic progression and the tumor microenvironment. These fundamental advances inform contemporary translational efforts in primary prevention, screening and early detection, multidisciplinary management and survivorship, as prospective clinical trials begin to adopt molecular-based selection criteria to guide targeted therapies.


The pancreatic cancer genome revisited.
Hayashi Akimasa et al. Nature reviews. Gastroenterology & hepatology 2021 6 (7) 469-481 (Posted: Jul 14, 2021 6AM)

Pancreatic cancer is a genetic disease, and the recurrent genetic alterations characteristic of pancreatic cancer indicate the cellular processes that are targeted for malignant transformation. In addition to somatic alterations in the most common driver genes (KRAS, CDKN2A, TP53 and SMAD4), large-scale studies have revealed major roles for genetic alterations of the SWI/SNF and COMPASS complexes, copy number alterations in GATA6 and MYC that partially define phenotypes of pancreatic cancer.


Expanding Germline Testing to All Patients With Esophagogastric Cancers—Easy to Do, Harder to Justify
JAMA Network Open, July 12, 2021 (Posted: Jul 13, 2021 7AM)

Guidelines currently support disease site–specific testing of patients with colorectal cancer younger than 50 years and all patients with pancreatic cancer. Testing patients with esophagogastric cancer (EGC), however, currently requires a known familial variant or a strong personal or family history indicative of a hereditary cancer syndrome, such as hereditary diffuse gastric cancer or Lynch syndrome.


BRCA2: a 25-year journey from gene identification to targeted cancer treatment.
Grinda Thomas et al. The Lancet. Oncology 2021 6 (6) 763-764 (Posted: Jun 06, 2021 7AM)

BRCA2 is the leading susceptibility gene for breast and ovarian cancer, with cumulative risks at age 80 years of up to 69% and 17%, respectively. Germline BRCA2 alterations can be found in around 2·5% of unselected patients with breast cancer and 6% of patients with ovarian cancer. To a lesser extent, deleterious BRCA2 variants also increase the risk of other cancers, including prostate, esophagus, and pancreatic cancer.


Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)
M Tishkowitz et al, Genetics in Medicine, May 11, 2021 (Posted: May 12, 2021 8AM)

PALB2 heterozygotes should be offered BRCA1/2-equivalent breast surveillance. Risk-reducing mastectomy can be considered guided by personalized risk estimates. Pancreatic cancer surveillance should be considered, but ideally as part of a clinical trial. Typically, ovarian cancer surveillance is not recommended, and risk-reducing salpingo-oophorectomy should only rarely be considered before the age of 50. Given the mechanistic similarities, PALB2 heterozygotes should be considered for therapeutic regimens and trials as those for BRCA1/2.


Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes
AM Varghese et al, JNCI, March 23, 2021 (Posted: Mar 24, 2021 10AM)

Pathogenic germ line variants are present in a substantial minority of patients with EOPC. Actionable somatic alterations were identified frequently in EOPC, enriched in the RAS wild-type subgroup. These observations underpin the recent guidelines for universal germline testing and somatic profiling in pancreatic ductal adenocarcinoma.


Looking to Long-term Survivors for Improved Pancreatic Cancer Treatment
BM Kuehn, JAMA, November 18, 2020 (Posted: Nov 19, 2020 11AM)

“Patients may only get one chance at chemotherapy, and we also need much more and better options for them. What we really want is a biomarker from the patient's tumor that would predict which [regimen] they're going to do better than average on and choose that one. This is not easy to find.”


Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA
GD Guler et al, Nature Comms, October 19, 2020 (Posted: Oct 20, 2020 7AM)

Pancreatic cancer is often detected late, when curative therapies are no longer possible. Here, we present non-invasive detection of pancreatic ductal adenocarcinoma (PDAC) by 5-hydroxymethylcytosine (5hmC) changes in circulating cell free DNA from a PDAC cohort (n?=?64) in comparison with a non-cancer cohort (n?=?243).


Personalized Treatments in Pancreatic Cancer: The Progress Continues
H Virgil, Oncology Nursing News, August 3, 2020 (Posted: Aug 04, 2020 9AM)

Although pancreatic cancer has been a historically difficult disease to treat, the emergence of novel combinations have allowed for more patients to receive later lines of therapy, and recent advances have inspired a shift to more personalized treatment approaches to improve outcomes.


An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice-A Review
M Rainone et al, JAMA Oncology, February 13, 2020 (Posted: Feb 14, 2020 8AM)

With increasing evidence and slow improvement of outcomes, PDAC has entered the era of precision medicine. Germline mutations have been identified in key genes with an aggregate frequency of 3.8% to 9.7%, several of which are therapeutically actionable with platinum, PARPi, and checkpoint inhibitor therapy.


Machine Learning and Network Analyses Reveal Disease Subtypes of Pancreatic Cancer and their Molecular Characteristics
M Sinkala et al, Scientific Reports, January 27, 2020 (Posted: Jan 28, 2020 7AM)

We use machine learning to define sets of proteins, mRNAs, miRNAs and DNA methylation patterns that could serve as biomarkers to differentiate pancreatic cancer subtypes. Itegrative profiling of multiple data types enables a biological and clinical representation that is comprehensive enough to provide a foundation for future therapeutic strategies.


New PARP Inhibitor Approval for Pancreatic Cancer
L Schlager, FORCE, January 6, 2020 (Posted: Jan 07, 2020 8AM)

The Food and Drug Administration approved olaparib– a type of targeted therapy known as a PARP inhibitor—for treatment of metastatic pancreatic cancer in people with a BRCA mutation. PARP inhibitors have been approved to treat ovarian cancer since 2014, and to treat metastatic breast cancer patients with a BRCA mutation since 2018.


The BRCA gene is about so much more than breast cancer risk
A Goldman, Well and Good, October 27, 2019 (Posted: Nov 01, 2019 10AM)

BRCA literally stands for “BReast CAncer gene,” so it makes sense that we think of a person’s breast cancer risk when we talk about BRCA gene mutations. The thing is, though, that harmful BRCA mutations can impact a person’s risk of developing several other cancers—including pancreatic cancer and prostate cancer—and they’re just less talked about.


Precision medicine in pancreatic cancer: treating every patient as an exception.
Herbst Brian et al. The lancet. Gastroenterology & hepatology 2019 Oct (10) 805-810 (Posted: Oct 16, 2019 6AM)

Patients with pancreatic cancer have not benefited from recent improvements in overall survival brought about by precision medicine in other malignancies. This failure is not due to a dearth of precision-medicine research in pancreatic ductal adenocarcinoma (PDAC), the main type of pancreatic cancer.


Pancreatic Cancer: Patient Page
JAMA, October 2019 (Posted: Oct 13, 2019 1PM)

Conditions that increase risk of pancreatic cancer include smoking, chronic pancreatitis, obesity, long-standing diabetes, a strong family history of pancreatic cancer, and diets high in red and processed meats.


A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer
H Nasief et al, NPJ Precision Oncology, October 4, 2019 (Posted: Oct 06, 2019 2PM)

Changes of radiomic features over time in longitudinal images, delta radiomics, can potentially be used as a biomarker to predict treatment response. This study aims to develop a delta-radiomic process based on machine learning by (1) acquiring and registering longitudinal images, (2) segmenting regions of interest, (3) and extracting radiomic features.


Predicting pancreatic cancer survival via the tumor microbiome
H Stover, Nature Medicine, Sepetmber 9, 2019 (Posted: Sep 10, 2019 9AM)


Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival
T Hamada et al, CEBP, August 2019 (Posted: Aug 29, 2019 8AM)


An Artificial Intelligence Tool to Improve Pancreatic Cancer Outcomes
S Rosen, Mato Clinic blog, August 13, 2019 (Posted: Aug 13, 2019 3PM)


Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer
S Nissim et al, Nature Genetics, August 12, 2019 (Posted: Aug 13, 2019 8AM)


PARP Inhibitors Hit the Pancreatic Cancer Scene
D Ternyila, Oncology Nursing News, August 9, 2019 (Posted: Aug 13, 2019 8AM)

PARP inhibitors, which have approved indications in breast and ovarian cancer, are expanding to additional treatment paradigms, including pancreatic cancer. Data from the phase III POLO trial showed that PARP inhibitor significantly improved progression-free survival among patients with germline BRCA-mutated metastatic pancreatic cancer.


Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
Riquelme Erick et al. Cell 2019 Aug (4) 795-806.e12 (Posted: Aug 12, 2019 8AM)


Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement.
et al. JAMA 2019 Aug (5) 438-444 (Posted: Aug 07, 2019 7AM)

USPSTF recommends against screening for pancreatic cancer in average risk persons. However, high-risk individuals may derive benefit from surveillance. These include familial pancreatic cancer, and those with mutations in several genes.


Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Henrikson Nora B et al. JAMA 2019 Aug (5) 445-454 (Posted: Aug 07, 2019 7AM)


Screening for Pancreatic Cancer.
Lucas Aimee L et al. JAMA 2019 Aug (5) 407-408 (Posted: Aug 07, 2019 7AM)


Screening for Pancreatic Cancer.
Jin Jill et al. JAMA 2019 Aug (5) 478 (Posted: Aug 07, 2019 7AM)


Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma.
Loft Matthew et al. Journal of personalized medicine 2019 Jul (3) (Posted: Jul 29, 2019 8AM)

The review focuses on the development of ctDNA as a non-invasive liquid biopsy, with potential clinical applications in pancreatic cancer. These include screening, prognostication via the detection of minimal residual disease, early detection of recurrence, and monitoring treatment response.


PARP inhibition - opportunities in pancreatic cancer.
Pant Shubham et al. Nature reviews. Clinical oncology 2019 Jul (Posted: Jul 26, 2019 9AM)

An urgent need exists to improve the survival of patients with pancreatic cancer through biomarker-driven therapeutic strategies. Such approaches include the targeting of metastatic pancreatic cancer that have germline BRCA mutations with poly(ADP-ribose) polymerase inhibitors.


Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localised pancreatic cancer.
Lee B et al. Annals of oncology : official journal of the European Society for Medical Oncology 2019 Jun (Posted: Jul 02, 2019 9AM)


Next-Generation Sequencing in Pancreatic Cancer.
Shen Gong-Qing et al. Pancreas 2019 Jul 48(6) 739-748 (Posted: Jun 19, 2019 9AM)


Pancreatic cancer therapy sheds light on the disease's ties to BRCA mutation
J Howard, CNN, June 2, 2019 (Posted: Jun 03, 2019 8AM)


Genetic Testing After a Terminal Diagnosis—Providing Purpose
J Solimine, JAMA Oncology, May 30, 2019 (Posted: May 31, 2019 10AM)


Early Detection Is Possible for Pancreatic Cancer
DM Simeone, New York Times, March 15, 2019 (Posted: Mar 16, 2019 5PM)


Proteomic and genomic profiling of pancreatic cancer.
Ansari Daniel et al. Cell biology and toxicology 2019 Feb (Posted: Mar 07, 2019 9AM)


Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer.
Ali Aesha I et al. Frontiers in oncology 2019 56 (Posted: Mar 07, 2019 8AM)


Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
Ohmoto Akihiro et al. International journal of molecular sciences 2019 Jan 20(3) (Posted: Feb 06, 2019 10AM)


Genetics of Familial and Sporadic Pancreatic Cancer.
Wood Laura D et al. Gastroenterology 2019 Jan (Posted: Jan 23, 2019 1PM)


Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
Roch Alexandra M et al. Journal of surgical oncology 2019 Jan (Posted: Jan 15, 2019 11AM)


Closing the Disparity in Pancreatic Cancer Outcomes: A Closer Look at Nonmodifiable Factors and Their Potential Use in Treatment.
Vick Alexis D et al. Pancreas 2019 Jan (Posted: Jan 14, 2019 8AM)


5 Things to Know About Hereditary Pancreatic Cancer
Pancreatic Cancer Action Network, November 2018 (Posted: Dec 02, 2018 10AM)


High prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer.
Bannon Sarah A et al. Cancer prevention research (Philadelphia, Pa.) 2018 Oct (Posted: Oct 03, 2018 8AM)


What You Need to Know About Genetic and Molecular Testing
A Rosenzweig, Pan Can, July 26, 2018 (Posted: Jul 29, 2018 8PM)


Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
Yurgelun Matthew B et al. Genetics in medicine : official journal of the American College of Medical Genetics 2018 Jul (Posted: Jul 03, 2018 11AM)


Pancreatic cancer as a sentinel for hereditary cancer predisposition.
Young Erin L et al. BMC cancer 2018 Jun 18(1) 697 (Posted: Jul 03, 2018 11AM)


Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative.
Pishvaian Michael J et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Jun (Posted: Jul 03, 2018 11AM)


Mayo Clinic discovers genetic links to pancreatic cancer
S Buckles, Mayo Clinic, June 19, 2018 (Posted: Jun 20, 2018 9AM)


Germline Genetic Testing for Pancreatic Ductal Adenocarcinoma at Time of Diagnosis
S Syngal et al, JAMA Oncology, JAMA, June 19, 2018 (Posted: Jun 20, 2018 8AM)


Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
C Hu et al, JAMA Oncology, June 19, 2018 (Posted: Jun 20, 2018 8AM)


Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis.
Signoretti Marianna et al. United European gastroenterology journal 2018 May 6(4) 489-499 (Posted: Jun 11, 2018 11AM)


PARP Inhibitor Shows Promise in Patients With BRCA-Mutated Pancreatic Cancer
ASCO Post, May 23, 2018 (Posted: May 25, 2018 8AM)


Five genetic changes linked to pancreatic cancer risk
Z Kassam, Drug Target Review, Feb 2018 (Posted: Mar 05, 2018 8AM)


Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer.
Klein Alison P et al. Nature communications 2018 Feb (1) 556 (Posted: Mar 03, 2018 9AM)


Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
DaVee Tomas et al. Gastrointestinal endoscopy 2018 Jan (Posted: Jan 10, 2018 9AM)


A genetic roadmap of pancreatic cancer: still evolving.
Notta Faiyaz et al. Gut 2017 Oct (Posted: Nov 04, 2017 0PM)


Circulating microRNAs Expressions as Genetic Biomarkers in Pancreatic Cancer Patients Continuous Non-Invasive Monitoring.
Sandesc Mihai et al. Clinical laboratory 2017 Oct (10) 1561-1566 (Posted: Nov 04, 2017 0PM)


Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
ZR Qiang et al, JAMA Oncology, Nov 3, 2017 (Posted: Nov 04, 2017 0PM)


5 Things to Know about BRCA Mutations and Pancreatic Cancer
Pancreatic Cancer Action Network, October 12, 2017 (Posted: Oct 16, 2017 6PM)


Familial pancreatic cancer: Concept, management and issues.
Matsubayashi Hiroyuki et al. World journal of gastroenterology 2017 Feb 23(6) 935-948 (Posted: Aug 16, 2017 8AM)


Genomics in Primary and Secondary Prevention of Pancreatic Cancer.
Malats Núria et al. Public health genomics 2017 Jul (Posted: Aug 09, 2017 6PM)


DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.
Golan Talia et al. Journal of the National Comprehensive Cancer Network : JNCCN 2017 Aug (8) 1063-1069 (Posted: Aug 09, 2017 6PM)


Dual-Biomarker Blood Test Shows Promise for Pancreatic Cancer Early Detection
NCI News, August 9, 2017 Brand (Posted: Aug 09, 2017 6PM)


Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history
KG Chaffee et al, Genetics in Medicine, July 20, 2017 (Posted: Jul 21, 2017 0PM)


Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer.
McAllister Florencia et al. Gastroenterology & hepatology 2017 May 13(5) 268-275 (Posted: Jul 05, 2017 9AM)


Lost in translation: returning germline genetic results in genome-scale cancer research
AL Johns et al, Genome Medicine, April 2017 (Posted: May 01, 2017 8AM)


Family History Helped This Survivor Catch Pancreatic Cancer Early- About 10 percent of pancreatic cancer cases are connected to family history.
Cellgene blog post, April 25, 2017 (Posted: Apr 26, 2017 8AM)


Genetics of Pancreatic Cancer and Its Implications on Therapy.
Tatarian Talar et al. The Surgical clinics of North America 2016 Dec (6) 1207-1221 (Posted: Apr 26, 2017 8AM)


Molecular Genetics of Pancreatic Neoplasms.
Hosoda Waki et al. Surgical pathology clinics 2016 Dec (4) 685-703 (Posted: Apr 26, 2017 8AM)


Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.
Khan Mohammad Aslam Aslam et al. International journal of molecular sciences 2017 Apr (4) (Posted: Apr 26, 2017 8AM)


New era in precision medicine for pancreatic cancer
Science, March 23, 2017 (Posted: Mar 23, 2017 10AM)


The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.
Martinez-Useros Javier et al. BioMed research international 2016 1869304 (Posted: Jan 20, 2017 1PM)


Circulating Tumor DNA May Serve as a Prognostic Marker in Pancreatic Cancer
J Cavallo, ASCO Post, December 20, 2016 (Posted: Dec 22, 2016 9AM)


Genetic factors affecting patient responses to pancreatic cancer treatment.
Fotopoulos George et al. Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology (4) 466-476 (Posted: Nov 01, 2016 10AM)


Learn About Hereditary Pancreatic Cancer
L Rezende, Facing Our Risk Empowered, November 1, 2016 (Posted: Nov 01, 2016 10AM)


Risk factors for pancreatic cancer include family history & genetics
American Cancer Society, 2016 (Posted: Nov 01, 2016 10AM)


Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai Erina et al. Advances in experimental medicine and biology 2016 92413-17 (Posted: Oct 26, 2016 10AM)


Advances in Hereditary Colorectal and Pancreatic Cancers.
Underhill Meghan L et al. Clinical therapeutics 2016 Jul (7) 1600-21 (Posted: Aug 17, 2016 0PM)


Pancreatic cancer biology and genetics from an evolutionary perspective.
Makohon-Moore Alvin et al. Nature reviews. Cancer 2016 Jul (Posted: Aug 17, 2016 0PM)


Can Pancreatic Cancer Be Inherited?
Dana Farber, August 16, 2016 (Posted: Aug 17, 2016 0PM)


Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program.
Joergensen Maiken Thyregod et al. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2016 Mar (Posted: Apr 27, 2016 10AM)


Genomic Testing for Gemcitabine-Based Treatment of Pancreatic Cancer
J Zhang et al, February 2016 (Posted: Mar 06, 2016 3PM)


Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.
Riva Francesca et al. Molecular oncology 2016 Mar (3) 481-93 (Posted: Mar 04, 2016 0PM)


Probing pancreatic cancer genomes
Genomics Education Program, February 29, 2016 (Posted: Feb 29, 2016 11AM)


Pancreatic cancer 'is four diseases'
R Bazeley, PHG Foundation, February 25, 2016 (Posted: Feb 25, 2016 6AM)


Genomic analyses identify molecular subtypes of pancreatic cancer
P Bailey et al, Nature, February 24, 2016 (Posted: Feb 24, 2016 1PM)


Functional annotation of rare gene aberration drivers of pancreatic cancer
YH Tsang et al, Nature Communications, January 25, 2016 (Posted: Jan 25, 2016 2PM)


Hereditary Pancreatic Cancer Syndromes.
Connor Ashton A et al. Surgical oncology clinics of North America 2015 Oct (4) 733-64 (Posted: Jan 25, 2016 2PM)


Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
Knudsen Erik S et al. Gastroenterology 2016 Jan (1) 48-63 (Posted: Jan 25, 2016 2PM)


Check out genetic conditions and tests associated with pancreatic cancer
from the NIH Genetic Testing Registry Brand (Posted: Aug 24, 2015 9AM)


Identification of Patients with Family History of Pancreatic Cancer - Investigation of an NLP System Portability.
Mehrabi Saeed et al. Stud Health Technol Inform 2015 216604-8 (Posted: Aug 19, 2015 0PM)


In a Former First Family, Cancer Has a Grim Legacy
D Grady, New York Times, August 7, 2015 (Posted: Aug 17, 2015 1PM)


more


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP